Integer Holdings Q2 Earnings Miss Estimates, Revenues Up Y/Y

Integer Holdings (ITGR) reported Q2 2025 revenues of $476.5 million, up 11.4% year-over-year and exceeding consensus, primarily driven by a 24% surge in its Cardio and Vascular segment due to acquisitions and electrophysiology. While adjusted EPS rose 19.2% year-over-year to $1.55, it missed consensus estimates by 1.3%. The company's 'Other Markets' segment declined significantly due to a planned exit, though overall adjusted operating margin expanded. Integer Holdings updated its full-year 2025 guidance, projecting revenues between $1.85 billion and $1.876 billion and adjusted EPS of $6.25 to $6.51.

Analysis

Integer Holdings (ITGR) reported mixed second-quarter 2025 results, characterized by strong top-line growth offset by a narrow earnings miss and margin pressure. Revenue grew 11.4% year-over-year to $476.5 million, beating consensus estimates by 2.9% on the back of robust organic growth of 10.8%. The primary driver was the Cardio and Vascular (C&V) segment, which surged 24% (17.6% organically), fueled by momentum in electrophysiology and recent acquisitions of Precision Coating and VSi Parylene. This strength was contrasted by modest 2.3% growth in the Cardiac Rhythm Management & Neuromodulation (CRM&N) segment and a significant 37.9% decline in the Other Markets segment, which was an expected outcome of a planned multi-year exit from the Portable Medical business. While adjusted EPS rose 19.2% to $1.55, it missed the consensus estimate by 1.3%. Profitability metrics were divergent; gross margin contracted 30 basis points to 27.1%, while adjusted operating margin expanded 50 basis points to 17.1%, reflecting improved operational leverage. The company's updated full-year 2025 guidance projects revenue growth of 8-9% and adjusted EPS growth of 18-23%, with consensus estimates falling within these new ranges.

Key Decisions for Investors

• Investors should focus on the strong performance and strategic importance of the Cardio and Vascular segment, whose 24% revenue growth is the core driver of the company's outlook and justification for its M&A strategy.
• It is prudent to monitor gross margin performance, as the 30 basis point contraction in Q2 poses a risk to profitability and could challenge the company's ability to meet its full-year EPS guidance of $6.25-$6.51 if the trend continues.
• Given the revenue beat but slight EPS miss, the 'Hold' rating suggests that while the strategic direction is positive, investors may wish to see evidence of stabilized margins before increasing exposure.